Table 2.
Sizing, zeta-potential and antifungal activity of drug, cationic lipid, and polyelectrolyte(s) assemblies
| Cationic lipid, drug and polyelectrolyte assemblies | D ± δ (nm) | ζ ± δ (mV) | Viability (%) |
| DODAB BF (0.6)/AmB (0.005)/CMC (1)/PDDA(1) | 171 ± 1 | 24 ± 2 | 79 ± 5 |
| DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL5000–10000 (1) | 92 ± 4 | 40 ± 1 | 71 ± 4 |
| DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL30000–70000 (1) | 138 ± 5 | 50 ± 3 | 21 ± 9 |
| DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL70000–150000 (1) | 148 ± 5 | 60 ± 3 | 13 ± 5 |
| AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PDDA (1) | 280 ± 2 | 35 ± 1 | 27 ± 2 |
| AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL5000–10000 (1) | 238 ± 1 | 25 ± 7 | 37 ± 1 |
| AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL30000–70000 (1) | 326 ± 5 | 36 ± 3 | 23 ± 6 |
| AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL70000–150000 (1) | 417 ± 3 | 47 ± 5 | 11 ± 3 |
Zeta-average diameter (D) and zeta-potential (ζ) of novel cationic AmB formulations and their effect on C. albicans viability at low and high drug-to-lipid molar proportions. Concentrations are given within parentheses in mg/mL. One should notice that polylysine (PL) with diferent molecular weights may alternatively replace PDDA and be used to control the positive zeta-potential of the outer layer.